logo

BCYC

Bicycle Therapeutics·NASDAQ
--
--(--)
--
--(--)
1.84 / 10
Underperform

BCYC's fundamental profile is concerning: key metrics like Total Operating Revenue (YoY -21.97%) and Operating Revenue (YoY -21.97%) rank in the weakest quartile, contributing to an overall fundamental score of 1.8/10 and an 'Underperform' stance. Only Days Sales Outstanding and Interest Coverage Ratio offer limited relief, but they are insufficient to offset the revenue decline and negative historical returns associated with these factors.

Fundamental(1.84)SentimentTechnical

Analysis Checks(5/10)

Revenue-MV
Value-1.95
Score1/3
Weight9.53%
1M Return4.24%
Total operating revenue (YoY growth rate %)
Value-21.97
Score1/3
Weight-1.39%
1M Return-0.79%
Days sales outstanding
Value72.55
Score2/3
Weight2.06%
1M Return1.10%
Profit-MV
Value0.46
Score2/3
Weight18.92%
1M Return8.45%
Net income-Revenue
Value-0.17
Score2/3
Weight18.94%
1M Return8.45%
PB-ROE
Value-0.35
Score1/3
Weight23.04%
1M Return9.57%
Interest coverage ratio (EBIT / Interest expense) (%)
Value15.48
Score2/3
Weight-1.89%
1M Return-1.11%
Operating revenue (YoY growth rate %)
Value-21.97
Score1/3
Weight-1.34%
1M Return-0.76%
Asset-MV
Value-0.50
Score0/3
Weight13.52%
1M Return5.75%
Cash-MV
Value-0.07
Score2/3
Weight18.60%
1M Return8.41%
Is BCYC undervalued or overvalued?
  • BCYC scores 1.84/10 on fundamentals and holds a Premium valuation at present. Backed by its -28.17% ROE, -884.51% net margin, -1.57 P/E ratio, 0.63 P/B ratio, and -10.37% earnings growth, these metrics solidify its Underperform investment rating.